• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017

    Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017

    • Report Code ID: RW0001689442
    • Category Healthcare
    • No. of Pages 47
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

    Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Diabetic Peripheral Neuropathy - Overview 6
    Diabetic Peripheral Neuropathy - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 9
    Products under Development by Companies 10
    Products under Development by Universities/Institutes 11
    Diabetic Peripheral Neuropathy - Therapeutics Assessment 12
    Assessment by Target 12
    Assessment by Mechanism of Action 14
    Assessment by Route of Administration 16
    Assessment by Molecule Type 18
    Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 20
    Achelios Therapeutics Inc 20
    Celgene Corp 20
    Commence Bio Inc 21
    KPI Therapeutics Inc 21
    Medifron DBT Co Ltd 22
    Relief Therapeutics Holding AG 22
    ViroMed Co Ltd 23
    Diabetic Peripheral Neuropathy - Drug Profiles 24
    atexakin alfa - Drug Profile 24
    Product Description 24
    Mechanism Of Action 24
    R&D Progress 24
    BNV-222 - Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    CMB-200 - Drug Profile 27
    Product Description 27
    Mechanism Of Action 27
    R&D Progress 27
    ketoprofen - Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    MDR-652 - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    ND-07 - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    PDA-002 - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    pirenzepine hydrochloride - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    Small Molecules for Pain - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    U-2902 - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    VM-202 - Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    Diabetic Peripheral Neuropathy - Dormant Projects 41
    Diabetic Peripheral Neuropathy - Discontinued Products 42
    Diabetic Peripheral Neuropathy - Product Development Milestones 43
    Featured News & Press Releases 43
    Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy 43
    Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 43
    Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 44
    Appendix 46
    Methodology 46
    Coverage 46
    Secondary Research 46
    Primary Research 46
    Expert Panel Validation 46
    Contact Us 46
    Disclaimer 47

    List of Tables

    Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2017 7
    Number of Products under Development by Companies, H1 2017 8
    Number of Products under Development by Universities/Institutes, H1 2017 9
    Products under Development by Companies, H1 2017 10
    Products under Development by Universities/Institutes, H1 2017 11
    Number of Products by Stage and Target, H1 2017 13
    Number of Products by Stage and Mechanism of Action, H1 2017 15
    Number of Products by Stage and Route of Administration, H1 2017 17
    Number of Products by Stage and Molecule Type, H1 2017 19
    Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2017 20
    Diabetic Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2017 20
    Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H1 2017 21
    Diabetic Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2017 21
    Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2017 22
    Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1 2017 22
    Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co Ltd, H1 2017 23
    Diabetic Peripheral Neuropathy - Dormant Projects, H1 2017 41
    Diabetic Peripheral Neuropathy - Discontinued Products, H1 2017 42

    List of Figures

    Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2017 7
    Number of Products under Development by Companies, H1 2017 8
    Number of Products by Top 10 Targets, H1 2017 12
    Number of Products by Stage and Top 10 Targets, H1 2017 12
    Number of Products by Top 10 Mechanism of Actions, H1 2017 14
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 14
    Number of Products by Routes of Administration, H1 2017 16
    Number of Products by Stage and Routes of Administration, H1 2017 16
    Number of Products by Molecule Types, H1 2017 18
    Number of Products by Stage and Molecule Types, H1 2017 18
    Achelios Therapeutics Inc
    Celgene Corp
    Commence Bio Inc
    KPI Therapeutics Inc
    Medifron DBT Co Ltd
    Relief Therapeutics Holding AG
    ViroMed Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//diabetic-peripheral-neuropathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diabetic-peripheral-neuropathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diabetic-peripheral-neuropathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments